ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has received a consensus rating of "Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.00.

Several research firms recently weighed in on PRQR. HC Wainwright lifted their price objective on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th. Evercore ISI initiated coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price target for the company. Oppenheimer lowered their price target on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a research note on Monday, March 10th. Finally, JMP Securities reissued a "market outperform" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research note on Friday, June 27th.

ProQR Therapeutics Stock Up 0.6%

PRQR traded up $0.01 on Monday, reaching $2.14. 175,653 shares of the company traded hands, compared to its average volume of 654,962. The company has a market cap of $225.47 million, a P/E ratio of -6.12 and a beta of 0.36. The firm has a fifty day simple moving average of $1.78 and a two-hundred day simple moving average of $1.94. ProQR Therapeutics has a one year low of $1.07 and a one year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 157.04% and a negative return on equity of 53.49%. The firm had revenue of $4.89 million during the quarter, compared to analysts' expectations of $4.90 million. On average, equities analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Trading of ProQR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC increased its position in ProQR Therapeutics by 699.3% during the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company's stock valued at $121,000 after buying an additional 79,720 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company's stock valued at $4,368,000 after acquiring an additional 459,512 shares in the last quarter. Walleye Capital LLC raised its position in shares of ProQR Therapeutics by 11.6% in the 1st quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company's stock valued at $670,000 after purchasing an additional 52,261 shares during the last quarter. Aberdeen Group plc purchased a new position in shares of ProQR Therapeutics in the 1st quarter valued at approximately $2,461,000. Finally, Persistent Asset Partners Ltd acquired a new stake in ProQR Therapeutics in the 1st quarter worth approximately $64,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).